Pegasus Biotech, a full-service biotechnology contract research organization, has recently introduced BPE plasmid technology that provides scientists with the ability to control the production of DNA. This new technology offers several advantages over existing methods, including the ability to increase replication levels significantly and achieve up to 7 times higher expression compared to traditional plasmid backbones.
Dr. Patrick Slaine, who led the development of this technology, emphasized its transformative potential in applications where cost of goods sold (COGS) and patient safety are critical factors. The BPE plasmid technology meets project requirements for low cost, minimal bacterial sequences, high expression, and no antibiotic resistance selection markers. This makes it an ideal choice for vaccine and gene-therapy product development.
Pegasus Biotech specializes in biopharmaceutical and vaccine development and offers services spanning seed-to-formulation process development and associated analytical development. The company is known for its expertise in vaccine and biopharmaceutical development and is a leader in DNA vaccine development.
For more information about Pegasus’ services or media inquiries, please contact Daniel Wilson at Pegasus Biotech Inc. at 1-855-498-3398 or via email at [email protected]. Visit their website at www.pegasusbio.com for more information on how they can help clients bring cutting-edge innovation to the human and animal health markets globally.
